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OBJECTIVE: Quality of life is not well studied in atrial
fibrillation (AF), the most prevalent rhythm disturbance
with significant impact on morbidity and mortality. We
report the development of a brief disease-specific QoL in-
strument for use in clinical trials, surveillance studies, and
clinical practice.
METHODS: Fifty-one items, based on literature, patient
focus groups, and a cardiology expert panel were admin-
istered via telephone interview to 73 chronic AF and 23
congestive heart failure (CHF), along with 25 angina con-
trol patients. 
RESULTS: Item reduction techniques produced the 20-item
AFIS comprising four symptom scales (dyspnea, fatigue, pal-
pitations syncope: 11 items) and three QoL scores measur-
ing functional, social and emotional impact (9 items). Inter-
nal consistencies were acceptable for all symptom scales
(Cronbach  0.73–0.77) and the QoL scales (Cronbach 
0.74–0.92). AFIS Total Symptom Impact (SI) score ex-
plained 50% of the variation in each QoL impact score
(R2  0.49 [functional], 0.44 [emotional], 0.55 [social]) and
75% (R2  0.74) of the total QoL impact (QI) score. We
identified two symptom impact (SI) threshold scores: mod-
erate AF impact (SI  40; sensitivity 0.86, 1-specificity 0.92)
and major AF impact (SI  60; sensitivity 0.96, 1-specificity
0.98). Mild symptomatic CAF patients (SI  40) reported
little QoL interference. Moderate symptomatic and major
symptomatic CAF patients had QI scores 200% and 665%
worse than the mild CAF patients. SI scores accounted for
50% (R2  0.50) and nearly 25% (R2  0.22) of total QI
variation in CHF and angina patients, respectively.
CONCLUSION: Mild AF symptoms are well tolerated.
However, moderate symptom impact (over 50% of pa-
tients) doubles the interference with QoL; while major
impact (33% of patients) approached a seven-fold wors-
ening of QoL. The Atrial Fibrillation Impact Scale ap-
pears to be a useful tool for predicting worsening QoL
among atrial fibrillation patients and for informing treat-
ment decisions.
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OBJECTIVE: With the increase of QoL assessment in
clinical trials, it is necessary to have cross-culturally valid
instruments to pool data across countries.
METHODS: The SAQ, a 19-item instrument designed in
US English, assesses five domains of coronary artery dis-
ease. Prior to use in an international trial, the original
had to undergo cultural adaptation, giving rise to 11 lan-
guage versions and a modified original. The cultural ad-
aptation process involved the recruitment of a QoL spe-
cialist in each country. Native speakers produced two
independent forward translations. These were reconciled
and back-translated into English. The translations were
tested for comprehension in a sample target population,
compared and internationally harmonized. The developer
of the SAQ clarified concepts underlying each item.
RESULTS: Translation problems involved finding con-
ceptual equivalents of typical US expressions and con-
structions and translating the original response catego-
ries. Examples for which a rationale of translation choice
and modification to the original will be discussed, are the
following: although activities such as “showering” and
“swimming” are less common outside the US, satisfac-
tory equivalents were found. The translation of “how sat-
isfied are you that everything is being done. . .,” however,
had to be rendered as “how convinced are you. . . .” It
was impossible to reproduce the original response scale
referring to “very, moderately, somewhat, a little, not at
all.” Equivalent answers in the translation had to refer to
“extremely, quite a bit, moderately, slightly, not at all.”
For reasons of comparability, the original was changed
accordingly. 
CONCLUSIONS: Before use in an international trial, rig-
orous cultural adaptation was essential to producing
cross-culturally valid language versions of the SAQ. This
process, entailing modifications to an already validated
original, might make further validation necessary. Fur-
ther responsiveness data will be generated by the clinical
trial. Ideally, initial instrument design should include in-
ternational input.
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OBJECTIVES: An analysis is being carried out to assess
the impact of clinical parameters, over and above the
treatment effect, in an evaluation of coronary heart dis-
ease (CHD) in German males.
METHODS: This analysis is part of a study which uses the
Coronary Heart Disease Risk Assessment Model (CHD
RAM), a decision analytical model, to evaluate the cost-
effectiveness of cholesterol-lowering agents for the primary
prevention of CHD in German males. Although the wider
study considers data for men in eight 5-year age groups
ranging from 35–39 to 70–74 years, the clinical sensitivity
analysis focuses on the 50–55 age group for three doses of
cerivastatin, a cholesterol-lowering agent. Baseline data
were primarily obtained from the published literature and
expert opinion. The clinical parameters—compliance rate
profiles, smoking behaviour, mean body mass index and
systolic blood pressure—will be assessed in terms of their
impact on CHD risk and life years gained. This will be esti-
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mated by initial low density lipoprotein (LDL) cholesterol
and the initial ratio of total cholesterol (TC) to high den-
sity lipoprotein (HDL) cholesterol.
RESULTS: Analyses will be conducted for each clinical pa-
rameter varying the parameters by appropriate amounts.
This will assess the robustness of the model and the impact
of key clinical parameters on baseline results. 
CONCLUSIONS: By separating behavioral factors from
treatment effect, the study will determine if clinical pa-
rameters play a major role in primary prevention of CHD
with cholesterol-lowering agents.
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OBJECTIVES: A study was undertaken to compare the
epidemiology and costs associated with primary preven-
tion of coronary heart disease (CHD) in males in France,
Germany, Italy, Spain, and the United Kingdom.
METHODS: Country-specific epidemiological and cost
data were collected as part of an economic evaluation of
CHD and analyzed for differences between countries. Ep-
idemiological and economic data were collected for men
in eight 5-year age groups (35–39 to 70–74 years). These
data were primarily obtained from the published litera-
ture and complemented by expert opinion.
RESULTS: Mean systolic blood pressure ranged from
125 to 132 for the 35–39 year olds and from 143.9 to
155.5 for the 70–74 year olds. Mean body mass index
ranged from 24.7 to 26.9 for the 35–39 year olds and
from 25.5 to 27.75 for the 70–74 year olds. The propor-
tion of smokers ranged from 0.38 to 0.56 for the 35–39
year olds and from 0.2 to 0.29 for the 70–74 year olds.
With adjustment by the respective health purchasing
power parities, direct costs of CHD ranged from £11,515
to £20,431 for acute myocardial infarction, £8,484 to
£17,898 for complicated angina, £606 to £10,227 for un-
complicated angina, and £305 to £9,734 for sudden and
nonsudden death. 
CONCLUSIONS: The epidemiological data showed simi-
lar trends within the five countries with some observed dif-
ferences for certain variables and/or age groups. Resource
utilization data differed significantly between countries—a
not surprising finding considering the profound differences
in healthcare systems and treatment patterns across Eu-
rope. In addition, differences in currency values and unit
costs make direct comparison of costs difficult.
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OBJECTIVE: We conducted a health economic and out-
comes study of post-menopausal women in Belgium to
quantify the benefits and risks associated with HRT. Us-
ing data provided by l’Université Catholique de Louvain,
the analysis was designed to predict the long-term clinical
and economic effects related to the conjugated estrogens/
medroxyprogesterone HRT (E/M HRT) regimen.
METHODS: Hypothetical cohorts of uterine-intact post-
menopausal women who were fully compliant with E/M
HRT were compared with similar cohorts of post-meno-
pausal women who did not use any form of HRT.
Markov cohort simulation analysis, guided by a Delphi
panel of local clinical and health economic experts, was
employed to model the short- and long-term implica-
tions of compliance with E/M HRT. Eight distinct health
states were considered in the analysis: healthy, osteo-
porosis, coronary heart disease, cerebrovascular disease,
Alzheimer’s Disease, breast cancer, colorectal cancer, and
death.
RESULTS: Results of this analysis suggest that patients
using E/M HRT therapy are expected to experience im-
proved health outcomes and an increased life expectancy
of more than 5 months per patient when compared those
not on HRT. These results are achieved with a modest
increase in cost of 8,415 BF, or 18,300 BF per life-year
gained.
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OBJECTIVE: To address willingness to pay (WTP) of pa-
tients with painful-irritable bladder syndrome (PIBS) us-
ing a regression model.
METHODS: A sample of 60 patients with PIBS from Se-
attle and Philadelphia were interviewed. The survey ques-
tionnaire contained a WTP question with 11 bids ranging
from $1 to $200. Two versions of the questionnaire were
administered, one for “improvement” of the condition
and one for “cure.” Respondents recorded whether they
would accept or reject each bid at the stated dollar value.
